Julie Schneider to Positron-Emission Tomography
This is a "connection" page, showing publications Julie Schneider has written about Positron-Emission Tomography.
Connection Strength
0.568
-
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol. 2014 Jan; 73(1):72-80.
Score: 0.116
-
Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis. 2014; 42(3):813-21.
Score: 0.116
-
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 Jan 19; 305(3):275-83.
Score: 0.095
-
Antemortem amyloid imaging and ?-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging. 2012 May; 33(5):878-85.
Score: 0.093
-
Age-related and amyloid-beta-independent tau deposition and its downstream effects. Brain. 2023 08 01; 146(8):3192-3205.
Score: 0.056
-
Genetic epistasis regulates amyloid deposition in resilient aging. Alzheimers Dement. 2017 Oct; 13(10):1107-1116.
Score: 0.036
-
Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol. 2014 Oct; 73(10):948-53.
Score: 0.031
-
Correlation of amyloid PET ligand florbetapir F 18 binding with A? aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012 Jan-Mar; 26(1):8-16.
Score: 0.025